NASDAQ:VTGN VistaGen Therapeutics Q1 2027 Earnings Results & Report $0.24 -0.01 (-4.10%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$0.24 0.00 (-0.04%) As of 10/9/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. VistaGen Therapeutics beat analyst expectations on both earnings and revenue in its Q1 2027 results, released August 14, 2026. The company reported EPS of -$0.30 versus the -$0.3650 consensus estimate, while revenue of $1.48 million topped the $0.50 million estimate by $0.98 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2027Report DateAugust 14, 2026TimeBefore Market OpensConference Call8:30 AM ET VistaGen Therapeutics EPS ResultsActual EPS-$0.30Consensus EPS -$0.3650Beat/MissBeat by +$0.0650One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersVistaGen Therapeutics Revenue ResultsActual Revenue$1.48 millionExpected Revenue$0.50 millionBeat/MissBeat by +$976.00 thousandYoY Revenue GrowthN/AUpcoming EarningsVistaGen Therapeutics' Q2 2027 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) VistaGen Therapeutics Q1 2027 Earnings FAQ Did VistaGen Therapeutics beat earnings estimates for Q1 2027? VistaGen Therapeutics (NASDAQ:VTGN) reported earnings of -$0.30 per share for Q1 2027, beating the consensus estimate of -$0.3650. The report was announced on Friday, August 14, 2026. What was VistaGen Therapeutics' revenue for Q1 2027? VistaGen Therapeutics reported revenue of $1.48 million for Q1 2027, against a consensus estimate of $0.50 million. When is VistaGen Therapeutics' next earnings date? VistaGen Therapeutics' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for VistaGen Therapeutics on the company's earnings history page. VistaGen Therapeutics Earnings HeadlinesVistaGen Therapeutics (NASDAQ:VTGN) Share Price Crosses Below 50 Day Moving Average - Should You Sell?October 7, 2026 | americanbankingnews.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Codexis (CDXS) and VistaGen Therapeutics (VTGN)September 24, 2026 | theglobeandmail.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain. | InvestorPlace (Ad)Vistagen Reports Positive Findings Supporting Fasedienol's Potential in Very Severe Social Anxiety DisorderSeptember 24, 2026 | globenewswire.comVistagen Reports Preliminary Data From Fasedienol Phase 3 Extension Study; Stock UpSeptember 22, 2026 | rttnews.comVistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety DisorderSeptember 22, 2026 | globenewswire.comSee More VistaGen Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like VistaGen Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VistaGen Therapeutics and other key companies, straight to your email. Email Address About VistaGen TherapeuticsVistaGen Therapeutics (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, with an emphasis on anxiety, depression and related conditions. The company is headquartered in South San Francisco, California, and conducts its development activities primarily in the United States. VistaGen’s lead product candidate is fasedienol, also known as PH94B, an investigational neuroactive nasal spray being developed for the treatment of social anxiety disorder and other anxiety-related conditions. The company’s approach is intended to provide rapid, non-systemic treatment through nasal administration. Fasedienol remains an investigational product and has not been approved for commercial sale. The company also maintains a broader neuroscience pipeline that has included other intranasal drug candidates, including PH80, as it evaluates potential treatments for psychiatric and neurological conditions. VistaGen’s programs are subject to clinical testing and regulatory review, and their development status may change as additional data become available. Shawn Singh serves as the company’s chief executive officer.View VistaGen Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
